Hyperbaric oxygen and telomere lengthening: what the study really found

What did @meteorclipss actually say?

The creator described a real study, broadly accurately, where participants underwent hyperbaric oxygen therapy (HBOT) and had their telomeres measured before and after. Their summary: 60 sessions over 90 days produced telomere lengthening "commensurate with a 20-year difference in their age." They also made a broader claim that this technology could help people live extraordinarily long lives, floating the idea of 30,000-year lifespans before walking it back.

The telomere finding is real and traceable to a published study. The longevity speculation, however, is where the video goes off the rails. Telomere length and human lifespan are not a simple dial you can turn up indefinitely.

Does the science back this up?

Partially, yes. The study the creator referenced is almost certainly Hachmo et al. (2020), published in Aging (Albany NY). Researchers at Tel Aviv University, not Jerusalem, put 35 healthy older adults through 60 HBOT sessions over 90 days. They found telomere length in peripheral blood mononuclear cells increased by an average of 20-38% depending on cell type, and senescent cell counts dropped. The researchers themselves framed this as equivalent to roughly 20 years of telomere aging reversed.

That is a legitimate finding from a peer-reviewed journal. The problem is the sample size: 35 people, no control group, and all results measured in blood cells only. It tells us something interesting happened. It does not tell us these people will live longer, healthier lives as a result. Telomere length in blood cells is a biomarker, not a verified proxy for overall biological age or lifespan.

What did they get wrong (or right)?

They got the core study detail largely right. The protocol, the 60-session structure, the telomere lengthening finding, and the rough 20-year equivalence claim all check out against the published literature. Credit where it is due: most people citing this study get the details more wrong than this creator did.

What they got wrong is the interpretive leap. Saying "the shorter your telomeres are, the closer you are to death" is an oversimplification. Telomere biology is genuinely complex. Short telomeres correlate with increased disease risk across population studies, but the relationship is probabilistic, not deterministic. More importantly, the creator slid from "telomeres lengthened in a small pilot study" to implying humans could someday live for tens of thousands of years. That is not a scientific inference. That is science fiction dressed up with a real citation.

They also placed the study in "Jerusalem" rather than Tel Aviv. Minor, but worth noting.

What should you actually know?

Telomere research is genuinely exciting and genuinely incomplete. The Hachmo study is real, but it is a small pilot trial. No long-term follow-up data exists showing that HBOT-induced telomere lengthening in blood cells translates to reduced disease burden, extended healthspan, or longer life. Larger, controlled trials have not replicated these findings at scale.

HBOT is an FDA-cleared treatment for specific conditions including wound healing, carbon monoxide poisoning, and radiation injury. Its use for anti-aging is considered investigational. It carries real risks including oxygen toxicity, barotrauma, and fire hazard. It is not a casual wellness tool.

If you are interested in telomere biology, the research worth reading includes Blackburn and Epel's work on lifestyle factors and telomere maintenance, and López-Otín et al. (2023) in Cell on the hallmarks of aging, which puts telomere attrition in proper context alongside a dozen other aging mechanisms. No single intervention addresses all of them.

Bottom line: is this worth your attention or your money?

The study is real. The single-study hype is not justified. One small pilot trial showing a biomarker change in blood cells does not establish HBOT as an anti-aging therapy. The 30,000-year lifespan comment is not science, it is content. If you are curious about HBOT for recovery or specific medical indications, that is a conversation worth having with a licensed provider. If you are chasing telomere lengthening as a longevity strategy based on one 35-person study, you are getting ahead of the evidence by a significant margin.